Exelixis
EXEL
NZ$74.33
Share price
-2.65%
Change (1 day)
89.04%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Exelixis (EXEL) - Total debt
Total debt on the balance sheet as of March 2025 : NZ$0.31 Billion
According to Exelixis's latest financial reports the company's total debt is NZ$0.31 Billion. A company’s total debt is the sum of all current and non-current debts.
Exelixis - Total debt on balance sheet (from 2000 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | NZ$0.33 B | 12.65% |
| 2023-12-31 | NZ$0.30 B | 0.28% |
| 2022-12-31 | NZ$0.29 B | 299.03% |
| 2021-12-31 | NZ$75.06 M | 10.34% |
| 2020-12-31 | NZ$68.02 M | -4.57% |
| 2019-12-31 | NZ$71.28 M | 220.58% |
| 2018-12-31 | NZ$22.23 M | 5.72% |
| 2017-12-31 | NZ$21.03 M | -92.3% |
| 2016-12-31 | NZ$0.27 B | -55.29% |
| 2015-12-31 | NZ$0.61 B | 34.03% |
| 2014-12-31 | NZ$0.45 B | 7.82% |
| 2013-12-31 | NZ$0.42 B | 3.54% |
| 2012-12-31 | NZ$0.40 B | 75.48% |
| 2011-12-31 | NZ$0.23 B | -13.93% |
| 2010-12-31 | NZ$0.27 B | 146.5% |
| 2009-12-31 | NZ$0.10 B | -45.94% |
| 2008-12-31 | NZ$0.20 B | 27.83% |
| 2007-12-31 | NZ$0.15 B | -8.13% |
| 2006-12-31 | NZ$0.17 B | -20.71% |
| 2005-12-31 | NZ$0.21 B | 5.46% |
| 2004-12-31 | NZ$0.20 B | 20.85% |
| 2003-12-31 | NZ$0.17 B | 20.96% |
| 2002-12-31 | NZ$0.14 B | 19.86% |
| 2001-12-31 | NZ$0.11 B | 249.37% |
| 2000-12-31 | NZ$33.73 M | 32.56% |
| 1999-12-31 | NZ$25.44 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 GlaxoSmithKline GSK | NZ$39.87 B | 12,627.21% | 🇬🇧 UK |
 Sanofi SNY | NZ$38.12 B | 12,068.60% | 🇫🇷 France |
 Merck MRK | NZ$58.34 B | 18,520.71% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$85.79 B | 27,282.23% | 🇺🇸 USA |
 Amgen AMGN | NZ$96.08 B | 30,564.53% | 🇺🇸 USA |
 Johnson & Johnson JNJ | NZ$87.49 B | 27,823.58% | 🇺🇸 USA |
 Pfizer PFE | NZ$102.63 B | 32,654.04% | 🇺🇸 USA |
 Curis CRIS | NZ$4.41 M | -98.59% | 🇺🇸 USA |
 AVEO Oncology
AVEO | NZ$64.76 M | -79.33% | 🇺🇸 USA |